---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Natural history, survival, and mortality"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Natural history, survival, and mortality. Topics: Bladder cancer mortality in the United States; Five-year relative survival overall and for in situ disease; Stage at diagnosis and five-year relative survival by stage, SEER 21, 2016 to 2022; Recurrence, progression, and bladder cancer mortality after high-grade NMIBC, SEER-Medicare; 14 further topics. 18 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Bladder cancer mortality in the United States

> “Bladder cancer mortality rates were stable from the 1990s until 2016 but have since declined by 1.4% per year.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

> “Bladder cancer is the tenth leading cause of cancer death in the United States.”
> “The death rate was 4.1 per 100,000 men and women per year.”
> “The percent of bladder cancer deaths is highest among people aged 75–84.”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-2.2.1.3-2"></a>

### Five-year relative survival overall and for in situ disease

> “The 5-year relative survival rate for bladder cancer is 79%, largely because half of cases are diagnosed in situ (still within the layer of cells where it originated), for which 5-year survival is 98%”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.3-3"></a>

### Stage at diagnosis and five-year relative survival by stage, SEER 21, 2016 to 2022

| Stage at diagnosis | Percent of cases | 5-year relative survival |
| --- | --- | --- |
| In situ | “50%” | “98.0%” |
| Localized | “34%” | “73.0%” |
| Regional | “7%” | “41.8%” |
| Distant | “6%” | “9.6%” |
| Unknown | “3%” | “50.8%” |

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-2.2.1.3-4"></a>

### Recurrence, progression, and bladder cancer mortality after high-grade NMIBC, SEER-Medicare

> “Of 7,410 subjects, 2,897 (39.1%) experienced a recurrence without progression, 2,449 (33.0%) experienced disease progression, of whom 981 succumbed to bladder cancer.”
> “Using competing-risks regression analysis, we found the 10-year recurrence, progression, and bladder cancer-related mortality rates to be 74.3%, 33.3%, and 12.3%, respectively.”
> “Nearly three-fourths of patients diagnosed with high-risk bladder cancer will recur, progress, or die within ten years of their diagnosis.”

Source: [Chamie et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3773281/)

<a id="topic-2.2.1.3-5"></a>

### Probability of progression at five years by prognostic risk group

> “From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%.”

Source: [Sylvester et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33419683/)

> “At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%.”

Source: [Sylvester et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16442208/)

<a id="topic-2.2.1.3-6"></a>

### Risk of progression and metastasis after BCG failure

> “Patients who are BCG-unresponsive are at high risk of progression to muscle-invasive bladder cancer (MIBC) and development of metastatic disease”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “Major guidelines recommend radical cystectomy (RC) with urinary diversion as the standard‐of‐care for BCG‐unresponsive NMIBC due to higher propensity for disease recurrence and progression”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.1.3-7"></a>

### Survival with BCG-unresponsive high-risk NMIBC, SEER-Medicare model input

> “Among adults with high-risk, BCG-unresponsive NMIBC, 92.6% and 81.2% remained alive at Years 2 and 3, respectively, based on an analysis of SEER Medicare claims data”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-2.2.1.3-8"></a>

### BCG-refractory compared with BCG-relapsing disease, prospective cohort

> “Seventeen patients were classified as BCG refractory and 15 patients defined BCG relapsing.”
> “Progression-free survival time was 18 months for BCG-refractory vs. 52 months for BCG-relapsing patients (P = 0.001). Of the 17 BCG-refractory patients, 8 (47%) have died vs. 3 (20%) of the 15 BCG-relapsing patients.”

Source: [Herr et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25813144/)

<a id="topic-2.2.1.3-9"></a>

### Progression and disease-specific death after T1 recurrence following BCG

> “In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.”
> “At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).”
> “In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy.”
> “At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).”

Source: [Raj et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17382713/)

<a id="topic-2.2.1.3-10"></a>

### Recurrence and progression with bladder-sparing therapy in BCG-unresponsive NMIBC, international multicenter cohort

> “Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months.”
> “There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups. In the BST group, high‐grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively.”
> “Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.1.3-11"></a>

### Long-term survival in BCG-unresponsive NMIBC, single-center registry

> “In total, 114 patients with a median follow-up of 71.2 mo (interquartile range: 32.6–132.2) were analyzed.”
> “There were no significant differences in OS (hazard ratio [HR]: 1.40, 95% confidence interval [CI]: 0.68–2.89, p = 0.4) or CSS (HR: 0.88, 95% CI: 0.22–3.55, p = 0.9) between patients undergoing early RC”
> “At 60 mo, BST patients had a high-grade recurrence-free rate, muscle-invasive disease/metastasis progression-free rate, and avoidance of RC rate of 37%, 83%, and 58%, respectively.”

Source: [Tan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10334230/)

<a id="topic-2.2.1.3-12"></a>

### Recurrence, progression, and cystectomy after BCG, US electronic health record and claims cohort

> “Among patients with recurrence, those who were BCG exposed accounted for 83.0% (366 of 441) of disease progression and 87.8% (337 of 384) of cystectomy cases.”

Source: [Giatsoglou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087816/)

<a id="topic-2.2.1.3-13"></a>

### Outcomes in BCG-exposed high-grade NMIBC not meeting the unresponsive definition, single-center cohort

> “In the BCG-E group, 50.2% experienced recurrence and 15.5% experienced progression; median recurrence-free survival (RFS) was 27.2 mo.”
> “The 5-yr survival rate estimates were 32.25% for RFS, 79.3% for progression-free survival (PFS), 84.5% for metastasis-free survival (MFS), and 65.0% for overall survival (OS).”

Source: [Jazayeri et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41421932/)

<a id="topic-2.2.1.3-14"></a>

### Clinical outcomes within 12 months of high-grade recurrence after BCG, prospective CISTO cohort

> “Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC.”
> “Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.”
> “Within 12 months, 27 (8.1%) participants in the BST arm underwent an eventual RC, including 21 (6.3%) for recurrent high-grade NMIBC and four (1.2%) for progression to MIBC”
> “Because 22% of patients undergoing RC had pathology demonstrating MIBC, 12-month progression-free survival (PFS) was lower for RC (73% v 92% for BST; wRR, 0.81 [95% CI, 0.74 to 0.88];”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.3-15"></a>

### Survival after radical cystectomy for BCG failure

> “We retrospectively analyzed the records of 117 patients who underwent radical cystectomy for recurrent nonmuscle invasive bladder cancer at our institution from 1990 to 2012.”
> “Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups.”

Source: [Haas et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26807928/)

> “Among 93 patients, 64 (68.8%) had clinical NMIBC, and 29 (31.2%) showed clinical progression to muscle-invasive bladder cancer (MIBC) prior to RC.”
> “Patients with pNMIBC had significantly better 5-year CSS (95.5%) and OS (77.6%) compared to those with clinical (CSS 70.4%, OS 50.2%) or subclinical progression (CSS 64.1%, OS 43.8%).”

Source: [Farré et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40947056/)

<a id="topic-2.2.1.3-16"></a>

### Salvage radical cystectomy compared with BCG rechallenge in BCG-unresponsive NMIBC, Japanese multicenter databases

> “In the adjusted BCG-unresponsive NMIBC cohort, no differences in MFS or OS were detected (p = 0.76 and p = 0.35, respectively), although long-term survival outcomes appeared better in the salvage RC group than in the BCG rechallenge group.”

Source: [Miyake et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41386721/)

<a id="topic-2.2.1.3-17"></a>

### Early mortality after radical cystectomy

> “The 30-d mortality rate was 1.5%.”

Source: [Shabsigh et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/18675501/)

<a id="topic-2.2.1.3-18"></a>

### Early mortality after radical cystectomy for muscle-invasive disease, National Cancer Database

> “Among 7922 patients, 90-day mortality was 7.6% (8.0% for lower and 6.7% for higher volume hospitals).”

Source: [Marqueen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349610/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
